BCL2 and acute lymphoblastic leukemia: BET bromodomain inhibition also affects BIM through the induction of BIM expression and reduced BCL-2 expression, with a resulting synergistic effect from venetoclax and the BET bromodomain inhibitor JO1 in T-ALL cell lines and the patient-derived xenograft [34].